Loading the session
Loading the session
Loading instrument
$27.39
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:43 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −15.1% (SPY −1.6%, XLV +13.5%). 3 months: −3.4% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALMR, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $27.39 was 9.8% below its 50-day average ($30.38).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
4 Nov 2026 volume of 1.5M shares was 2.1× the average of the 30 sessions before it (737.2K), as the price fell 9.4%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
2.7M shares were sold short at the 15 Oct 2026 settlement; covering them would take 3.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
October 7, 2026
−13.92%October 6, 2026
−15.39%August 11, 2026
+30.65%